Tarandeep Anand is the CEO of Adam’s Love Global Foundation for MSM (men who have sex with men) and Transgender Health (ALGO). Since 2008, Tarandeep has been a driving force in Asia for implementing technology-based HIV outreach projects and conducting technology-focused HIV prevention, health and behavioral research among key populations in Indonesia, Japan, Malaysia, South Korea, Thailand and Taiwan. His work at Adam’s Love has been highlighted as a successful case study within the World Health Organization’s (WHO) “Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations” and has helped outline key considerations for innovative prevention and care programs utilizing communication technology to address the HIV prevention and treatment needs of MSM and transgender persons. His key contributions to science over the past decade include a novel ‘online-to-offline’ (O2O) model for pre-exposure prophylaxis (PrEP) and HIV testing scale up, completely online HIV prevention and treatment cascade using Adam’s Love Electronic Health Record (EHR), Thailand’s first online HIV self-testing implementation science research, technology-based risk reduction intervention via Vialogues.com, Electronic Directly Observed Therapy (e-DOT) for PrEP adherence, and fast-track post-exposure prophylaxis (PEP) service delivery model. Tarandeep’s works are widely published in high-impact journals and he has been invited as a plenary speaker to showcase innovative service delivery models at several international platforms, including the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2016, UK), the European AIDS Conference (EACS 2019 in Basel, Switzerland), the International AIDS Conference (AIDS 2016 in Durban, South Africa), and the Bangkok International Symposium on HIV Medicine.